Skip to main content

Table 1 Pregnancy characteristics and safety rates of the 3 groups

From: Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission

  Group A Group B Group C P
Subjects, n 62 61 65 -
Age, y 28.9 ± 11.8 29.7 ± 9.8 27.5 ± 12.9 0.559
Infection duration, y 15.3 ± 10.9 16.1 ± 9.9 15.7 ± 11.5 0.919
Gravidity, n 1.8 ± 1.2 1.8 ± 1.1 1.8 ± 1.3 0.369
Delivery, n 1.1 ± 0.2 1.1 ± 0.1 1.1 ± 0.4 0.369
Gestational age, wk 39.0 ± 1.0 39.3 ± 1.2 39.2 ± 1.1 0.308
Adverse pregnancy, % 12.9(8/62) 11.4(7/61) 13.8(9/65) 0.923
Postparum hemorrhage, % 17.7(11/62) 14.7(9/61) 18.4(12/65) 0.844
Cesarean section, % 19.3(12/62) 16.4(10/61) 20.0(13/65) 0.859